(-0.13%) 5 301.50 points
(-0.04%) 40 127 points
(-0.21%) 18 465 points
(0.43%) $81.70
(-1.51%) $1.692
(0.17%) $2 216.40
(-0.89%) $24.53
(-0.31%) $906.85
(0.44%) $0.928
(0.72%) $10.85
(0.35%) $0.794
(-0.14%) $92.31
@ $9.02
Issued: 14 Feb 2024 @ 14:04
Return: 61.20%
Previous signal: Feb 14 - 09:30
Previous signal:
Return: 0.89 %
Live Chart Being Loaded With Signals
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...
Stats | |
---|---|
Today's Volume | 1.33M |
Average Volume | 785 745 |
Market Cap | 710.92M |
EPS | $0 ( 2024-02-15 ) |
Next earnings date | ( $-0.800 ) 2024-04-11 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.49 |
ATR14 | $0.0430 (0.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-16 | Van Houte Hans | Sell | 6 812 | Common Stock |
2024-02-13 | Van Houte Hans | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Van Houte Hans | Buy | 45 000 | Restricted Stock Units |
2024-02-13 | Ring Christine | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Ring Christine | Buy | 45 000 | Restricted Stock Units |
INSIDER POWER |
---|
91.85 |
Last 100 transactions |
Buy: 2 499 418 | Sell: 108 263 |
Volume Correlation
Nurix Therapeutics, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nurix Therapeutics, Inc. Correlation - Currency/Commodity
Nurix Therapeutics, Inc. Financials
Annual | 2023 |
Revenue: | $76.99M |
Gross Profit: | $63.33M (82.26 %) |
EPS: | $-2.65 |
Q4 | 2023 |
Revenue: | $15.16M |
Gross Profit: | $11.40M (75.22 %) |
EPS: | $-0.770 |
Q3 | 2023 |
Revenue: | $18.47M |
Gross Profit: | $15.08M (81.68 %) |
EPS: | $-0.680 |
Q2 | 2023 |
Revenue: | $30.68M |
Gross Profit: | $27.34M (89.13 %) |
EPS: | $-0.400 |
Financial Reports:
No articles found.
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators